NewCelX

Company Overview

Snapshot

Founded in October 2008 by Michel Revel, NewCelX operates with 11–50 employees. The company has raised $45.35 million across 9 funding rounds from 11 investors. In October 2025, NewCelX completed a reverse merger with NLS Pharmaceutics Ltd. and subsequently listed on NASDAQ.

Business overview

NewCelX is a biotechnology company focused on developing innovative cell-based and small-molecule therapies. The company leverages advanced stem-cell technologies and neuroscience expertise to create regenerative treatments. NewCelX primarily targets neurodegenerative and metabolic diseases, including Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes, operating within the Health Tech & Life Sciences sector.

Strategic signal

In October 2025, NewCelX completed a reverse merger with NLS Pharmaceutics Ltd., leading to its listing on NASDAQ. This strategic move provides NewCelX with access to public markets, potentially accelerating the development and commercialization of its cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The merger signifies a major step in the company's growth trajectory and its ability to attract broader investor interest.

Company Intelligence Q&A

What was a significant corporate development for NewCelX in late 2025?

In October 2025, NewCelX completed a reverse merger with NLS Pharmaceutics Ltd. and subsequently became publicly listed on NASDAQ.

What was the outcome of the shareholder meeting for the merger with Kadimastem?

In September 2025, NLS Pharmaceutics shareholders approved the merger with Kadimastem (now NewCelX) and related proposals at an extraordinary general meeting.

Has NewCelX received any recent patent approvals for its diabetes treatment technology?

In September 2025, NewCelX (formerly Kadimastem) and NLS Pharmaceutics announced a Hong Kong patent covering cell-selection and enrichment technology for IsletRx, a treatment for diabetes patients.

What was the nature of the collaboration announced in October 2025?

In October 2025, NLS Pharmaceutics and Kadimastem (now NewCelX) announced a strategic collaboration with TargetGene to advance next-generation gene-edited cell therapies.

What regulatory submission did NewCelX make in May 2026?

In May 2026, NewCelX Ltd. submitted a Pre-IND (Investigational New Drug) package to the FDA for NCEL-101, a treatment for Type 1 Diabetes.